Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Average Recommendation of “Moderate Buy” from Brokerages

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has been assigned an average recommendation of “Moderate Buy” from the four research firms that are covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $51.33.

A number of research analysts have commented on AGIO shares. StockNews.com downgraded shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, August 5th. The Goldman Sachs Group lifted their price target on Agios Pharmaceuticals from $33.00 to $53.00 and gave the stock a “neutral” rating in a research note on Tuesday, June 4th. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Friday, September 20th. Leerink Partners lowered Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $60.00 to $56.00 in a research report on Friday. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $55.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, September 19th.

Insiders Place Their Bets

In other news, CEO Brian Goff sold 11,091 shares of the company’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total transaction of $474,140.25. Following the completion of the transaction, the chief executive officer now directly owns 78,792 shares of the company’s stock, valued at $3,368,358. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.93% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of AGIO. Farallon Capital Management LLC lifted its position in Agios Pharmaceuticals by 1.1% in the 2nd quarter. Farallon Capital Management LLC now owns 5,654,502 shares of the biopharmaceutical company’s stock valued at $243,822,000 after purchasing an additional 63,900 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Agios Pharmaceuticals by 0.8% in the first quarter. Vanguard Group Inc. now owns 5,572,021 shares of the biopharmaceutical company’s stock valued at $162,926,000 after purchasing an additional 44,583 shares during the period. Armistice Capital LLC boosted its position in shares of Agios Pharmaceuticals by 6.0% during the fourth quarter. Armistice Capital LLC now owns 3,524,000 shares of the biopharmaceutical company’s stock worth $78,479,000 after buying an additional 200,000 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of Agios Pharmaceuticals by 23.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,012,993 shares of the biopharmaceutical company’s stock worth $58,861,000 after buying an additional 388,381 shares during the period. Finally, First Trust Advisors LP grew its holdings in Agios Pharmaceuticals by 2.4% in the 4th quarter. First Trust Advisors LP now owns 1,818,643 shares of the biopharmaceutical company’s stock worth $40,501,000 after buying an additional 43,476 shares in the last quarter.

Agios Pharmaceuticals Stock Performance

NASDAQ:AGIO opened at $48.05 on Friday. Agios Pharmaceuticals has a one year low of $19.80 and a one year high of $53.28. The business’s 50-day simple moving average is $45.70 and its 200 day simple moving average is $39.58. The stock has a market cap of $2.73 billion, a price-to-earnings ratio of -7.60 and a beta of 0.75.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.60) by ($0.09). Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. The business had revenue of $8.60 million for the quarter, compared to analysts’ expectations of $9.34 million. During the same quarter last year, the company posted ($1.51) earnings per share. The business’s quarterly revenue was up 28.4% compared to the same quarter last year. On average, equities research analysts predict that Agios Pharmaceuticals will post -4.85 EPS for the current year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.